Avexitide
Also known as: AC162352, Avexitide, Exendin 9-39, Exendin‑9‑39, Exendin(9-39)
Source Avexitide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Avexitide is a synthetic 31‑amino‑acid peptide (exendin‑9‑39 analog) that antagonizes the GLP‑1 receptor. It is being studied for the treatment of hypoglycaemia, including congenital hyperinsulinism and post‑bariatric hypoglycaemia.
Mechanism of Action
Competitive antagonism at the glucagon-like peptide‑1 (GLP‑1) receptor, blocking GLP‑1‑mediated insulin secretion and glucose lowering
Routes of Administration
Goals & Uses
- Treatment of post-bariatric hypoglycemiaMetabolic / EndocrineModerate
- Reduction of postprandial insulin secretionMetabolic / EndocrineModerate
- Management of congenital hyperinsulinismGeneticModerate
- Post‑bariatric hypoglycaemia therapyPost‑surgicalModerate
- Research tool for GLP-1 physiologyResearchHigh
- Congenital hyperinsulinismMetabolic / EndocrineLow
- Control of hypoglycaemiaMetabolicModerate
Contraindications
- Known hypersensitivity to avexitide or any excipientsAllergyHigh
- Type 2 diabetes mellitusEndocrineModerate
- Type 1 diabetes mellitusEndocrineModerate
- Hypersensitivity to exendin-based peptidesAllergyHigh
Adverse Effects
- HyperglycemiaMetabolicUncommonAbnormally high blood glucose
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
Drug Interactions
- Insulin and insulin secretagoguesModerate
- DPP‑4 inhibitorsModerate
- GLP‑1 receptor agonists (e.g., exenatide, liraglutide)High
- GLP-1 receptor agonists (e.g., semaglutide, liraglutide, exenatide)High
- SulfonylureasLowMay increase risk of low blood sugar
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical study under EMA oversight; not approved
- United StatesInvestigationalPhase 2 trials for hypoglycaemia; not FDA‑approved
- United KingdomInvestigationalNot approved by MHRA; no UK-specific authorization as of knowledge cutoff
Not approved in any jurisdiction; currently in Phase 2 clinical trials in the US and EU. Received Fast‑Track designation from the FDA for hypoglycaemia indications.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Avexitide?
Avexitide is a synthetic 31‑amino‑acid peptide (exendin‑9‑39 analog) that antagonizes the GLP‑1 receptor. It is being studied for the treatment of hypoglycaemia, including congenital hyperinsulinism and post‑bariatric hypoglycaemia.
What is Avexitide used for?
Avexitide is educationally associated with: Treatment of post-bariatric hypoglycemia, Reduction of postprandial insulin secretion, Management of congenital hyperinsulinism, Post‑bariatric hypoglycaemia therapy, Research tool for GLP-1 physiology, Congenital hyperinsulinism, Control of hypoglycaemia. Educational only — not medical advice.
How is Avexitide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Avexitide?
Reported adverse effects include: Hyperglycemia, Injection site reactions, Headache, Nausea, Vomiting. This list is not exhaustive — consult a qualified clinician.
Who should avoid Avexitide?
Recorded contraindications: Known hypersensitivity to avexitide or any excipients, Type 2 diabetes mellitus, Type 1 diabetes mellitus, Hypersensitivity to exendin-based peptides. Consult a qualified clinician before use.